CES attendees saw health-tracking gadgets making bold promises: toothbrushes detecting diabetes, mirrors assessing 20-year ...
TÜV Rheinland has introduced a closed-loop recycled material verification process to help the electronics industry manage growing e-waste volumes and comply with increasingly strict regulatory demands ...
Our Lady Of Lourdes Heart Hospital relocated its Electrophysiology Lab, expanding advanced AFib and heart rhythm care for ...
Luma Vision announced that it completed 15 AFib ablation procedures as part of a clinical study in collaboration with CardioFocus.
Makers of smartwatches and other wearables have spent years trying to measure blood sugar without pricking your skin. The ...
The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.
Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.
AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteersPhase 2 trial will assess ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback